Asset Details
Do you wish to reserve the book?
抗乙肝病毒新药Bay41-4109在HBV转基因小鼠中的药效学研究
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
抗乙肝病毒新药Bay41-4109在HBV转基因小鼠中的药效学研究
Do you wish to request the book?
抗乙肝病毒新药Bay41-4109在HBV转基因小鼠中的药效学研究
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
抗乙肝病毒新药Bay41-4109在HBV转基因小鼠中的药效学研究
2011
Overview
目的研究抗乙肝病毒新药Bay41-4109在HBV转基因小鼠体内的药效学作用。方法 SPF级TgM（HBV D1.3）小鼠分为Bay41-4109组[30mg/（kg.d）],拉米夫定组[30mg/（kg.d）]和溶媒组（0.5%羧甲基纤维素钠）3组,每组32只。利用免疫组化分析HBV转基因小鼠肝组织HBcAg变化,定量PCR技术研究HBV转基因小鼠肝组织HBV DNA及血清HBV DNA的变化,并从血清转氨酶及体重指标分析该药物体内作用的安全性。结果给药第50天,Bay41-4109组HBcAg阳性细胞核个数、阳性细胞核平均面积、光密度比值三项指标均明显低于溶媒组（P〈0.05）;用药第64天（停药2周）,各组间上述三项指标均无统计学差异。拉米夫定组各时间点上述指标与溶媒组之间均无明显差异（P〉0.05）。但Bay41-4109对肝组织及血清HBV DNA未见明显作用。该药未对HBV转基因小鼠血清转氨酶及体重产生明显影响。结论 Bay41-4109可有效抑制HBV转基因小鼠肝组织HBcAg表达,且效果优于拉米夫定。Bay41-4109是一种安全性较好的抗乙肝新药,其作用机制不同于拉米夫定。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.